T3 Pharmaceuticals develops bacteria-based immuno-oncology therapies built on a proprietary protein delivery platform that repurposes the bacterial type III secretion (T3S) system. The company’s live bacterial vehicles are optimized to accumulate and grow selectively at solid tumors, where they produce and deliver chosen therapeutic proteins into eukaryotic cells. Its lead candidate, T3P-Y058-739, is the first therapeutic developed using the platform and is planned to enter a Phase 1/2 study in solid tumors in early 2021. T3 Pharma will use the new proceeds primarily to progress T3P-Y058-739 through clinical studies. The company closed its third financing round raising over 25M CHF and has raised a total of 40M CHF since its 2015 launch as a spin-off from the University of Basel. Investors in the latest round include the Boehringer Ingelheim Venture Fund, Reference Capital SA, Wille Finance AG and private investors. T3 Pharmaceuticals develops a proprietary protein delivery technology using live bacteria that express the type 3 secretion system to grow selectively within solid tumors and produce therapeutic proteins. The company’s lead product, T3P-Y058-739, originated from the T3 platform and is completing preclinical work. T3 expects the lead candidate to enter clinical testing in mid-2020 and is preparing to progress into the clinical phase. To support that transition it has strengthened its development team, appointed Claire Barton as Chief Medical Officer, and assembled a clinical advisory board of leading clinician scientists. T3 recently closed a second financing round of over CHF12 million to fund completion of preclinical activities and clinical planning. The company works in collaboration with the Biozentrum of the University of Basel for continued support during development.

Total raised

$39M

Funding rounds

2

Latest round

Equity

Latest activity

Jul 2020